Skip to main content

Table 3 Previous use of osteoporosis and analgesic medications

From: Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS)

Characteristic

Colombia

(N = 277)

Brazil

(N = 130)

Mexico

(N = 83)

Argentina

(N = 56)

All Patients Latin America Subregion (N = 546)

Past use of osteoporosis medicationa, n (%)

181 (65.3%)

96 (73.8%)

58 (69.9%)

52 (92.9%)

387 (70.9%)

Number of previous osteoporosis medications, n (%)

0

96 (34.7%)

34 (26.2%)

25 (30.1%)

4 (7.1%)

159 (29.1%)

1

95 (34.3%)

29 (22.3%)

12 (14.5%)

10 (17.9%)

146 (26.7%)

2

60 (21.7%)

39 (30.0%)

14 (16.9%)

23 (41.1%)

136 (24.9%)

3

20 (7.2%)

24 (18.5%)

11 (13.3%)

17 (30.4%)

72 (13.2%)

4

5 (1.8%)

4 (3.1%)

17 (20.5%)

1 (1.8%)

27 (4.9%)

5 or more

1 (0.4%)

0 (0.0%)

4 (4.8%)

1 (1.8%)

6 (1.1%)

Previous pharmacotherapy for osteoporosisb, n (%)

Alendronate

31 (11.2%)

37 (28.5%)

20 (24.1%)

6 (10.7%)

94 (17.2%)

Ibandronate

23 (8.3%)

3 (2.3%)

9 (10.8%)

11 (19.6%)

46 (8.4%)

Risedronate

4 (1.4%)

10 (7.7%)

4 (4.8%)

6 (10.7%)

24 (4.4%)

Zoledronate

21 (7.6%)

6 (4.6%)

23 (27.7%)

1 (1.8%)

51 (9.3%)

Other bisphosphonates

1 (0.4%)

1 (0.8%)

1 (1.2%)

2 (3.6%)

5 (0.9%)

Any one or more bisphosphonates

73 (26.4%)

49 (37.7%)

46 (55.4%)

22 (39.3%)

190 (34.8%)

Calcitonin

3 (1.1%)

3 (2.3%)

1 (1.2%)

0 (0.0%)

7 (1.3%)

Calcium only

119 (43.0%)

65 (50.0%)

34 (41.0%)

39 (69.6%)

257 (47.1%)

Denosumab

13 (4.7%)

0 (0.0%)

8 (9.6%)

5 (8.9%)

26 (4.8%)

Raloxifene

0 (0.0%)

1 (0.8%)

3 (3.6%)

0 (0.0%)

4 (0.7%)

Strontium ranelate

2 (0.7%)

4 (3.1%)

1 (1.2%)

2 (3.6%)

9 (1.6%)

Vitamin D only

82 (29.6%)

61 (46.9%)

31 (37.3%)

45 (80.4%)

219 (40.1%)

Use of ≥1 back pain medication over the past 24 h, n (%)

94 (33.9%)

23 (17.7%)

24 (28.9%)

26 (46.4%)

167 (30.6%)

Specific back pain medications, n (%)

NSAIDs

11 (4.0%)

6 (4.6%)

19 (22.9%)

14 (25.0%)

50 (9.2%)

Paracetamol

66 (23.8%)

5 (3.8%)

10 (12.0%)

8 (14.3%)

89 (16.3%)

Opioids

22 (7.9%)

2 (1.5%)

0 (0.0%)

4 (7.1%)

28 (5.1%)

Paracetamol and opioid combination

2 (0.7%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

2 (0.4%)

  1. N = total number of patients available; n = number of patients with valid (non-missing or unknown) values; NSAIDs = nonsteroidal anti-inflammatory drugs
  2. aThis includes ongoing medications as well as those stopped before baseline
  3. bPrior osteoporosis medications taken by > 0.5% of all patients in the overall Latin American subregional cohort
  4. Note: Percentages are calculated using n, the number of valid (not missing or unknown) responses for each item